Literature DB >> 33160069

Arginine vasopressin receptor 2 activation promotes microvascular permeability in sepsis.

Ernesto Lopez1, Satoshi Fukuda1, Katalin Modis2, Osamu Fujiwara1, Baigal Enkhtaivan1, Raul Trujillo-Abarca1, Koji Ihara3, Francisco Lima-Lopez2, Dannelys Perez-Bello1, Csaba Szabo4, Donald S Prough1, Perenlei Enkhbaatar5.   

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) sepsis is a severe condition associated with vascular leakage and poor prognosis. The hemodynamic management of sepsis targets hypotension, but there is no specific treatment available for vascular leakage. Arginine vasopressin (AVP) has been used in sepsis to promote vasoconstriction by activating AVP receptor 1 (V1R). However, recent evidence suggests that increased fluid retention may be associated with the AVP receptor 2 (V2R) activation worsening the outcome of sepsis. Hence, we hypothesized that the inhibition of V2R activation ameliorates the severity of microvascular hyperpermeability during sepsis. The hypothesis was tested using a well-characterized and clinically relevant ovine model of MRSA pneumonia/sepsis and in vitro assays of human lung microvascular endothelial cells (HMVECs). in vivo experiments demonstrated that the treatment of septic sheep with tolvaptan (TLVP), an FDA-approved V2R antagonist, significantly attenuated the sepsis-induced fluid retention and markedly reduced the lung water content. These pathological changes were not affected by the treatment with V2R agonist, desmopressin (DDAVP). Additionally, the incubation of cultured HMVECs with DDAVP, and DDAVP along with MRSA significantly increased the paracellular permeability. Finally, both the DDAVP and MRSA-induced hyperpermeability was significantly attenuated by TLVP. Subsequent protein and gene expression assays determined that the V2R-induced increase in permeability is mediated by phospholipase C beta (PLCβ) and the potent permeability factor angiopoietin-2. In conclusion, our results indicate that the activation of the AVP-V2R axis is critical in the pathophysiology of severe microvascular hyperpermeability during Gram-positive sepsis. The use of the antagonist TLVP should be considered as adjuvant treatment for septic patients. The results from this clinically relevant animal study are highly translational to clinical practice.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Keywords:  Endothelium; Microvascular hyperpermeability; Sepsis; Shock; Tolvaptan

Mesh:

Substances:

Year:  2020        PMID: 33160069      PMCID: PMC8075069          DOI: 10.1016/j.phrs.2020.105272

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  51 in total

Review 1.  Endothelial barrier dysfunction in septic shock.

Authors:  S M Opal; T van der Poll
Journal:  J Intern Med       Date:  2015-03       Impact factor: 8.989

2.  G protein subunits and the stimulation of phospholipase C by Gs-and Gi-coupled receptors: Lack of receptor selectivity of Galpha(16) and evidence for a synergic interaction between Gbeta gamma and the alpha subunit of a receptor activated G protein.

Authors:  X Zhu; L Birnbaumer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

3.  Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis*.

Authors:  Sascha David; Aditi Mukherjee; Chandra C Ghosh; Midori Yano; Eliyahu V Khankin; Julia B Wenger; S Ananth Karumanchi; Nathan I Shapiro; Samir M Parikh
Journal:  Crit Care Med       Date:  2012-11       Impact factor: 7.598

4.  Evaluation of endothelial biomarkers as predictors of organ failures in septic shock patients.

Authors:  Aurore Palud; Erika Parmentier-Decrucq; Jean Pastre; Nathalie De Freitas Caires; Philippe Lassalle; Daniel Mathieu
Journal:  Cytokine       Date:  2015-03-17       Impact factor: 3.861

5.  Unlike arginine vasopressin, the selective V1a receptor agonist FE 202158 does not cause procoagulant effects by releasing von Willebrand factor.

Authors:  Sebastian Rehberg; Perenlei Enkhbaatar; Janina Rehberg; Erin La; Nicky Ferdyan; Steve Qi; Kazimierz Wisniewski; Lillian D Traber; Claudio D Schteingart; Pierre J M Rivière; Régent Laporte; Daniel L Traber
Journal:  Crit Care Med       Date:  2012-06       Impact factor: 7.598

Review 6.  Emerging therapies for the treatment of sepsis.

Authors:  Jean-Louis Vincent
Journal:  Curr Opin Anaesthesiol       Date:  2015-08       Impact factor: 2.706

7.  Oxidant-induced cardiomyocyte injury: identification of the cytoprotective effect of a dopamine 1 receptor agonist using a cell-based high-throughput assay.

Authors:  Domokos Gerö; Katalin Módis; Nóra Nagy; Petra Szoleczky; Zoltán Dóri Tóth; György Dormán; Csaba Szabó
Journal:  Int J Mol Med       Date:  2007-11       Impact factor: 4.101

8.  Peroxynitrite decomposition catalyst reduces vasopressin requirement in ovine MRSA sepsis.

Authors:  Osamu Fujiwara; Satoshi Fukuda; Ernesto Lopez; Yaping Zeng; Yosuke Niimi; Douglas S DeWitt; David N Herndon; Donald S Prough; Perenlei Enkhbaatar
Journal:  Intensive Care Med Exp       Date:  2019-09-09

9.  Human mesenchymal stem cells reduce the severity of acute lung injury in a sheep model of bacterial pneumonia.

Authors:  Sven Asmussen; Hiroshi Ito; Daniel L Traber; Jae W Lee; Robert A Cox; Hal K Hawkins; Daniel F McAuley; David H McKenna; Lillian D Traber; Hanjing Zhuo; Jennifer Wilson; David N Herndon; Donald S Prough; Kathleen D Liu; Michael A Matthay; Perenlei Enkhbaatar
Journal:  Thorax       Date:  2014-06-02       Impact factor: 9.139

Review 10.  Bench-to-bedside review: Angiopoietin signalling in critical illness - a future target?

Authors:  Matijs van Meurs; Philipp Kümpers; Jack J M Ligtenberg; John H J M Meertens; Grietje Molema; Jan G Zijlstra
Journal:  Crit Care       Date:  2009-03-09       Impact factor: 9.097

View more
  3 in total

1.  Terlipressin: Hopes Fulfilled or Dashed?

Authors:  Raimund H Pichler; Erik R Swenson; Peter J Leary; Cary H Paine
Journal:  Clin J Am Soc Nephrol       Date:  2021-11-17       Impact factor: 8.237

2.  Ultrasound evaluation of endothelial dysfunction in immunoglobulin-resistant children with acute Kawasaki disease.

Authors:  Yizhou Wen; Yanfeng Yang; Yang Wen; Jimei Xi; Tingting Chen; Yaheng Lu; Li Wang; Yiling Liu; Feifei Si
Journal:  Clin Rheumatol       Date:  2022-08-18       Impact factor: 3.650

3.  Desmopressin Stimulates Nitric Oxide Production in Human Lung Microvascular Endothelial Cells.

Authors:  Bianca Maria Rotoli; Rossana Visigalli; Francesca Ferrari; Marianna Ranieri; Grazia Tamma; Valeria Dall'Asta; Amelia Barilli
Journal:  Biomolecules       Date:  2022-03-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.